Swissmedic publishes Information concerning an official Warning from Brazil regarding Falsified Medicinal Product
Recommendation

8 September 2026
Basel, Switzerland
Specifics in the Distribution of Medicinal Products
The Swissmedic has been informed by the Brazilian Health Regulatory Agency ANVISA that Brazil has suspended all imports of medicinal products from three Turkish wholesalers. The reason for this is the export of falsified units from Turkey to Brazil. One of the batches was also obtained from Turkey and sold to Brazil by a Swiss wholesaler.
In this regard, an information for Swiss companies was published. The Swissmedic points out that Swiss companies are also not permitted to supply medications obtained from the Turkish wholesalers to Brazil.
The names of the three wholesalers and further information can be found on the website of Swissmedic.
Related GMP News
14.07.2026USP Proposes to Revise the Definition of Controlled Room Temperature in Chapter <659>
14.07.2026GDP in Hong Kong: Authority Provides Additional Information
14.07.2026GDP Inspection Responses: MHRA’s Expectations for AI Use in GxP Replies
14.07.2026FDA Warning Letter to Amazon: Unapproved New Drugs Sold via Online Marketplace
18.06.2026GDPA Participated as an Observer in the EMA GMDP-IWG Interested Parties Meeting


